‘Not woke stuff': Trump administration bars US officials from Australia defence talks
National security experts fear an array of exchanges between US and Australian counterparts will dry up following a sweeping Pentagon edict, announced this week, suspending all participation in think tank and research events because it suspects they do not align with Donald Trump's 'America First' agenda.
The edict comes as the US reviews the future of the AUKUS nuclear-powered submarine pact and Prime Minister Anthony Albanese prepares for a potential first meeting with Trump in September after months of no discussions between the pair.
US and Australian officials were planning to meet some of the nations' top defence experts in Canberra on Monday and Tuesday next week for the fifth round of the US-Australia Indo-Pacific Deterrence Dialogue, but the event was suddenly called off on Wednesday when the American officials were told they were no longer allowed to travel to the event.
Around 40 American and Australian national security figures would have gathered to discuss issues such as military integration, nuclear deterrence and strategic interaction with China at the closed-door dialogue, which involved months of planning.
The so-called '1.5 track' event brings together current military leaders, government officials and diplomats with non-government researchers. Discussions are held under the Chatham House rule to foster frank discussions on sensitive and complex topics, with the participants' identities kept secret.
This would have been the first time the dialogue has been held since Trump's re-election.
Chief Pentagon spokesman Sean Parnell said in a statement: 'In order to ensure the Department of Defence is not lending its name and credibility to organisations, forums, and events that run counter to the values of this administration, the Department's Office of Public Affairs will be conducting a thorough vetting of every event where Defence officials are invited to participate.'
Rory Medcalf, head of the Australian National University's National Security College, said the 'cancellation of this dialogue is disappointing and counterproductive for alliance interests'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
27 minutes ago
- Sydney Morning Herald
‘A very big threat': Australia defends PBS as Trump flags 250% tariffs on medicines
Health Minister Mark Butler is planning to speed up medicines approvals as United States President Donald Trump threatens to put tariffs of up to 250 per cent on pharmaceutical products, which could affect $2 billion worth of Australian exports. Butler said Trump's latest threat would not change the discount Australians received on medicines through the Pharmaceutical Benefits Scheme, but revealed he would get advice within days about accelerating the approvals process for new drugs in Australia – a key issue that US pharmaceutical giants have raised with Trump. Speeding up the timeframe for US medicines to land on pharmacy shelves could improve the Australian government's standing with the Trump administration, although it does not deal with the White House's bigger concern that Americans pay more for medicines than citizens of other countries. Trump's anger with what he called 'foreign freeloading nations' prompted him to threaten tariffs of up to 250 per cent on drug imports this week. Butler said it was a 'a very big threat'. 'It's one we're working very hard to engage with the Americans on,' Butler said on Thursday. Loading 'The numbers are jumping around … They were 200 per cent a couple of weeks ago, and now they're 250 per cent potentially. They are very, very big tariffs. 'We are making the case very strongly, but I'm not going to pretend that the US Administration doesn't appear to be pretty serious about this.' Australia's PBS – under which the government subsidises drugs and Australians can buy expensive medicines for a maximum price of $31.60, soon to become $25 – has been brought up repeatedly during Trump's trade wars as US pharmaceutical companies push the president to punish countries that limit their market access.
Sydney Morning Herald
27 minutes ago
- Sydney Morning Herald
‘Bad timing': US-India tensions throw Albanese-Trump meeting into doubt
Prime Minister Anthony Albanese's plans to meet US President Donald Trump in India next month have been thrown into turmoil by the intensifying trade battle between Washington and New Delhi, raising doubts about the future of a four nation grouping's ability to counter China. Trump announced on Thursday that he would double tariffs on Indian exports to the United States to 50 per cent, among the highest in the world, to punish the nation for buying oil from Russia, sparking an angry reaction from New Delhi. Indian Prime Minister Narendra Modi has been preparing to host the leaders of Australia, the US and Japan for a summit of the Quad grouping in early September, providing a platform for Albanese's first in-person meeting with Trump. The Quad leaders have met every year since 2021 as part of the high-profile partnership designed to showcase the ability of the nations to work together as a democratic counterweight to authoritarian China's growing influence in the Indo-Pacific. Beijing has loathed the Quad since its inception, blasting it as an 'exclusive clique' and falsely characterising it as an 'Asian NATO', although the group is not underpinned by a treaty. Ian Hall, an expert on Indian politics at Griffith University, said it was 'a toss up' whether the September summit, which has not been formally confirmed, would go ahead given the rising hostility between Trump and Modi, who until recently revelled in a seemingly friendly relationship. 'The Quad is going to have to come up with a whole new agenda and to find a way to hold a summit in India. It's very unclear if that will happen,' he said. 'For 25 years, the US has seen India's rising prosperity and influence as being in its interests. That has just disappeared under 'America first' and that's a big problem.' Albanese tried to meet Trump to discuss issues including tariffs and AUKUS at a meeting of the G7 group of countries in June, but the president left early as conflict escalated in the Middle East.
The Age
27 minutes ago
- The Age
‘A very big threat': Australia defends PBS as Trump flags 250% tariffs on medicines
Health Minister Mark Butler is planning to speed up medicines approvals as United States President Donald Trump threatens to put tariffs of up to 250 per cent on pharmaceutical products, which could affect $2 billion worth of Australian exports. Butler said Trump's latest threat would not change the discount Australians received on medicines through the Pharmaceutical Benefits Scheme, but revealed he would get advice within days about accelerating the approvals process for new drugs in Australia – a key issue that US pharmaceutical giants have raised with Trump. Speeding up the timeframe for US medicines to land on pharmacy shelves could improve the Australian government's standing with the Trump administration, although it does not deal with the White House's bigger concern that Americans pay more for medicines than citizens of other countries. Trump's anger with what he called 'foreign freeloading nations' prompted him to threaten tariffs of up to 250 per cent on drug imports this week. Butler said it was a 'a very big threat'. 'It's one we're working very hard to engage with the Americans on,' Butler said on Thursday. Loading 'The numbers are jumping around … They were 200 per cent a couple of weeks ago, and now they're 250 per cent potentially. They are very, very big tariffs. 'We are making the case very strongly, but I'm not going to pretend that the US Administration doesn't appear to be pretty serious about this.' Australia's PBS – under which the government subsidises drugs and Australians can buy expensive medicines for a maximum price of $31.60, soon to become $25 – has been brought up repeatedly during Trump's trade wars as US pharmaceutical companies push the president to punish countries that limit their market access.
